Free Trial

Amedisys (AMED) Competitors

Amedisys logo
$97.67 -0.22 (-0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$97.67 0.00 (0.00%)
As of 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMED vs. DVA, CHE, CRVL, MD, AMN, CCRN, LH, DGX, EHC, and ELAN

Should you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Labcorp (LH), Quest Diagnostics (DGX), Encompass Health (EHC), and Elanco Animal Health (ELAN).

Amedisys vs. Its Competitors

DaVita (NYSE:DVA) and Amedisys (NASDAQ:AMED) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

DaVita currently has a consensus price target of $164.50, suggesting a potential upside of 14.74%. Amedisys has a consensus price target of $100.75, suggesting a potential upside of 3.15%. Given DaVita's higher probable upside, equities analysts plainly believe DaVita is more favorable than Amedisys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DaVita
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Amedisys
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

DaVita has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$12.82B0.84$936.34M$10.0914.21
Amedisys$2.35B1.37$43.23M$2.7136.04

DaVita has a net margin of 6.63% compared to Amedisys' net margin of 3.79%. DaVita's return on equity of 176.11% beat Amedisys' return on equity.

Company Net Margins Return on Equity Return on Assets
DaVita6.63% 176.11% 4.66%
Amedisys 3.79%12.52%7.01%

In the previous week, DaVita had 1 more articles in the media than Amedisys. MarketBeat recorded 3 mentions for DaVita and 2 mentions for Amedisys. DaVita's average media sentiment score of 1.30 beat Amedisys' score of -0.64 indicating that DaVita is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DaVita
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amedisys
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

90.1% of DaVita shares are held by institutional investors. Comparatively, 94.4% of Amedisys shares are held by institutional investors. 2.0% of DaVita shares are held by company insiders. Comparatively, 2.1% of Amedisys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

DaVita beats Amedisys on 9 of the 15 factors compared between the two stocks.

Get Amedisys News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMED vs. The Competition

MetricAmedisysMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.21B$3.88B$5.56B$9.04B
Dividend YieldN/A1.31%5.25%4.03%
P/E Ratio36.0422.8319.5820.23
Price / Sales1.3799.43442.27127.79
Price / Cash15.7123.7037.5058.41
Price / Book2.714.388.085.60
Net Income$43.23M$189.47M$3.16B$248.43M
7 Day Performance1.59%-1.64%3.77%5.15%
1 Month Performance0.86%-5.65%3.90%7.62%
1 Year Performance-0.23%7.29%34.22%21.56%

Amedisys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMED
Amedisys
2.5948 of 5 stars
$97.67
-0.2%
$100.75
+3.2%
+0.7%$3.21B$2.35B36.0419,000
DVA
DaVita
4.367 of 5 stars
$142.71
+0.1%
$164.50
+15.3%
+3.0%$10.77B$12.82B14.1476,000Positive News
CHE
Chemed
4.9756 of 5 stars
$461.20
-2.5%
$645.00
+39.9%
-10.5%$6.75B$2.43B22.4615,695
CRVL
CorVel
1.4709 of 5 stars
$100.00
-2.8%
N/A+19.7%$5.14B$895.59M54.455,075
MD
Pediatrix Medical Group
1.9976 of 5 stars
$13.44
-2.5%
$16.67
+24.0%
+100.3%$1.15B$2.01B-13.314,305Positive News
AMN
AMN Healthcare Services
4.2334 of 5 stars
$21.23
-3.1%
$32.08
+51.1%
-54.6%$812.68M$2.98B-4.902,968Gap Down
CCRN
Cross Country Healthcare
4.1075 of 5 stars
$12.75
-2.0%
$17.93
+40.6%
-5.6%$417.95M$1.34B-24.068,205
LH
Labcorp
4.4578 of 5 stars
$257.78
-1.6%
$276.08
+7.1%
+30.1%$21.58B$13.01B29.8070,000Trending News
Dividend Announcement
Analyst Forecast
Analyst Revision
DGX
Quest Diagnostics
4.9122 of 5 stars
$173.78
-1.8%
$185.73
+6.9%
+25.4%$19.40B$9.87B21.9756,000Positive News
Ex-Dividend
Analyst Revision
EHC
Encompass Health
4.9672 of 5 stars
$119.22
+0.2%
$127.00
+6.5%
+39.9%$12.02B$5.37B24.6340,000Positive News
ELAN
Elanco Animal Health
2.391 of 5 stars
$14.48
-1.1%
$15.33
+5.9%
+9.1%$7.19B$4.44B19.579,000

Related Companies and Tools


This page (NASDAQ:AMED) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners